MYC regulation of a “poor-prognosis” metastatic cancer ce

Communicated by Dennis A. Carson, University of California at San Diego, La Jolla, CA, January 9, 2009 ↵1A.E.A. and I.G. contributed equally to this work. (received for review December 16, 2008) ArticleFigures SIInfo asterisk in figure; t Edited by Pierre A. Joliot, Institut de Biologie Physico-Chemique, Paris, France, and approved July 19, 2005 (received for review April 27, 2005) ArticleFigures SIInfo currently, the resolution is 3.2 Å (4). The structure of the PSII RC sh

Contributed by Joan S. Brugge, December 18, 2009 (sent for review November 3, 2009)

↵1A.W. and B.S.W. contributed equally to this work.

Article Figures & SI Info & Metrics PDF

Abstract

Gene expression signatures are used in the clinic as prognostic tools to determine the risk of individual patients with localized breast tumors developing distant metastasis. We lack a clear understanding, however, of whether these correlative bioImpressers link to a common biological network that regulates metastasis. We find that the c-MYC oncoprotein coordinately regulates the expression of 13 different “poor-outcome” cancer signatures. In addition, functional inactivation of MYC in human breast cancer cells specifically inhibits distant metastasis in vivo and invasive behavior in vitro of these cells. These results suggest that MYC oncogene activity (as Impressed by “poor-prognosis” signature expression) may be necessary for the translocation of poor-outcome human breast tumors to distant sites.

breast cancerbioImpressersinvasion and migrationtranscriptional profiling

Over the past decade, 13 different multigene “poor-outcome” cancer signatures have been identified using DNA microarray–based gene expression profiling (1 –12). Quantitative increases in the expression of these different signatures within a primary tumor are correlated with its likelihood of metastasis to distant sites across a spectrum of different solid tumor types (Fig. 1A ). Some of these prognostic signatures, including the 21-gene Oncotype Dx and 70-gene MammaPrint gene sets, were derived from breast tumors and have been deployed as bioImpressers for risk stratification in patients with newly diagnosed breast cancer (6, 9 –11). However, many other such signatures were originally derived using a variety of experimental Advancees, have individually been associated with varying aspects of cancer progression (i.e., transformation, proliferation, dedifferentiation/stemness, genetic instability, and metastasis), are prognostic in malignancy beyond breast cancer, and appear to overlap minimally with respect to component genes (Fig. S1 and Table S1). Thus, whether these 13 different signatures as a set link to a common biological network related to metastasis remains unclear.

Fig. 1.Fig. 1.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Molecular regulation of 13 poor-outcome human cancer signatures. (A) Thirteen different signatures (designated s1–s13), correlated with different biological processes associated with metastatic progression, reported to be prognostic in different tumor types (green). To simplify the analysis, we first created two “metagenes” by separately averaging up-regulated and Executewn-regulated genes from each multigene poor-outcome cancer signature (s1–s13). (B–J) Plots displaying UP and ExecuteWN metagenes derived from each signature in standard deviation units after (B) 17β-estradiol stimulation (red circles) versus control (blue diamonds) in MCF7 cells, (C) ERBB2 overexpression (red circles) versus control (blue diamonds) in MCF10A cells, (D) EGF stimulation (red circles) versus control (blue diamonds) in MCF10A cells, (E) DHT stimulation (red circles) versus control (blue diamonds) in LNCaP cells, (F) 17β-estradiol stimulation and CHX treatment (red circles) versus CHX treatment alone (blue diamonds) in MCF7 cells, (G) overexpression of MYC (red circles) versus vector control (blue diamonds) in MCF7 cells, (H) overexpression of ZIP (red circles) versus vector control (blue diamonds) in MCF7 cells, (I) siRNA knockExecutewn of enExecutegenous MYC (red circles) versus vector control (blue diamonds) in MCF7 cells, and (J) siRNA knockExecutewn of enExecutegenous MYC (red circles) versus vector control (blue diamonds) in MDA-MB-231 cells. Circles and diamonds represent independent replicates. s2, s7, and s9 are unidirectional signatures that have only up-regulated genes.

Results

Although these 13 “poor-prognosis” signatures were derived in various ways, many without any relation to breast cancer, most are prognostic across different breast tumor expression data sets. A few of these signatures also are coordinately expressed in the same high-risk human breast tumors (13). Necessaryly, many poor-prognosis signatures contain genes whose expression correlates with estrogen receptor (ER) status in breast cancer, and estrogen signaling is known to drive the growth and survival of breast cancer cells from the earliest stages of disease (14). These observations led to the hypothesis that estrogenic signaling may regulate the expression of both signatures derived from breast tumors and other diverse signatures derived in non–breast cancer contexts. To test this hypothesis, we assayed the expression of the 13 poor-outcome tumor signatures using Affymetrix microarrays in estrogen-dependent ERα+/β− MCF7 breast cancer cells after experimental manipulation of estrogenic signaling (15).

Detailed statistical analysis revealed that a significant proSection of genes in each of these 13 different transcriptional signatures was indeed expressed by MCF7 cells and was tightly and coordinately regulated by signaling through the ER (Fig. 1B , Figs. S2 and S3, and Table S2). Different signatures overlapped by no more than 10% with respect to individual component genes (Fig. S1). Furthermore, even this minimal overlap between different signatures could not account for the coordinate pattern that we observed, which was far beyond chance based on permutation analysis using both ranExecutem and unrelated, experimentally derived signature sets (Table S3). Overall, approximately 40% of all poor-outcome signature genes were estrogen-regulated in MCF7 cells, with proSections in individual signatures ranging from around 30% to Arrively 100% (Table S2). These initial findings in a cancer cell–autonomous experimental system demonstrated that the ER can functionally regulate the coordinate expression of a majority of poor-prognosis signatures.

Beyond ER, we also observed similar transcriptional Traces with other oncogenes. For example, ERBB2 overexpression and EGF stimulation in MCF10A breast epithelial cells, which are immortalized but untransformed, both induced coordinated expression of all 13 poor-outcome signatures (Fig. 1 C and D ), and stimulation of LNCaP prostate cancer cells with dihydrotestosterone (DHT) via the androgen receptor (AR) produced a similar transcriptional pattern, albeit somewhat more weakly than ERBB2 or EGF signaling with respect to the “ExecuteWN” metagenes from different signatures (Fig. 1E ). These results suggested that increased activity of four different oncogenic pathways known to independently regulate cancer cell growth and survival in different cellular contexts could push different epithelial cell types toward a common transcriptional state defined by the coordinate expression of 13 different poor-outcome signatures.

We next investigated whether poor outcome signature regulation reflected direct or indirect Traces of these oncogenes on transcription. ERBB2 and EGFR, as membrane-bound receptor tyrosine kinases, almost certainly induced poor-outcome signature expression indirectly by signaling through Executewnstream transcription factors. In Dissimilarity, ERα and AR are nuclear hormone receptors whose transcriptional activity can be modulated by the EGFR and ERBB2 pathways, raising the possibility that these transcription factors might directly regulate poor-outcome signature expression. But treatment of MCF7 cells with 17β-estradiol in the presence of cycloheximide (CHX), a general inhibitor of new protein translation, Ruined coordinated signature induction by estrogen (Fig. 1F ) (16). These results demonstrated that ERα might modulate poor-outcome signature expression indirectly, at least in part through a common transcriptional regulator Executewnstream of the ERα, ERBB2, EGFR, and AR pathways.

Consequently, we analyzed the ERα-, ERBB2-, EGFR-, and AR-regulated transcriptional profiles in further detail, to identify candidate genes from the 13 poor-outcome signatures whose expression was commonly induced in response to these four different stimuli. Overall, approximately 50% of the poor-outcome signature genes were regulated by these different pathways across different cellular contexts. Although some poor-outcome genes were regulated uniquely by one of these pathways, others were commonly regulated by multiple pathways. In particular, ERα, ERBB2, EGFR, and AR commonly induced the expression of a “core gene set” of 20 poor-outcome genes, which was far beyond ranExecutem (P = 1.6 × 10−12) (Fig. 2A ).

Fig. 2.Fig. 2.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

MYC-centered core interactome. (A) Venn diagram illustrating derivation of the core gene set. (B) A highly connected network of the 20 genes in the core gene set (orange) and 13 associated genes identified using the IPA algorithm (17). MYC is highlighted in red. (C) Statistical analysis of genome-wide MYC-binding site data obtained from MCF7 cells after stimulation with 17β-estradiol, generated using ChIP-Chip (chromatin immunoprecipitation and tiling microarrays spanning the entire nonrepetitive human genome) (26). UP and ExecuteWN poor-outcome signature genes with at least one MYC binding site within ± 5 kb of their transcription start site (orange) versus the same for all other genes on the tiling array (green).

Although this core gene set did not contain any obvious candidate transcriptional regulators, all of the genes in this set were linked into a single and highly-connected “core interactome” using the IPA algorithm and database of literature-based molecular interactions (Fig. 2B ) (17). This core interactome was highly connected to the MYC transcription factor, which was not a member of any poor-outcome signature and thus was not in the core gene set itself. This correlation fit with the observation that at least 10 of 20 core interactome genes are known direct MYC tarObtains (www.myccancergene.org). It also was consistent with previous reports implicating MYC as a regulator of poor-prognosis signature expression in breast cancer (18 –22). Taken toObtainher, this evidence raised the hypothesis that MYC, which is Executewnstream of the ERα, ERBB2, EGFR, and AR pathways, may act as a common transcriptional regulator for expression of the 13 different poor-outcome signatures that we studied.

Consistent with this hypothesis, overexpression of MYC in MCF7 cells was sufficient to induce coordinated poor-prognosis signature expression (Fig. 1G ) (23). In Dissimilarity, overexpression of ZIP (a MYC mutant lacking the two N-terminal transactivation Executemains) in MCF7 cells failed to induce this expression pattern (Fig. 1H ). Furthermore, siRNA knockExecutewn of enExecutegenous MYC in MCF7 (ER+) reversed this coordinated pattern of signature expression (Fig. 1I ) (24, 25). Overall, these transcriptional changes involved 20% of all poor-outcome signature genes in MCF7 cells, ranging from 10% to 40% across individual signatures (Table S4). In addition, analysis of genome-wide MYC chromatin immunoprecipitation microarray (ChIP-Chip) profiling data, obtained from MCF7 cells after 17β-estradiol treatment (26), demonstrated a highly significant enrichment for MYC binding within 5 kb of the transcriptional start sites of up-regulated poor-outcome signature genes (P = 6 × 10−8) (Fig. 2C ). In Dissimilarity, we found no similar enrichment in MYC binding for Executewn-regulated poor-outcome genes, suggesting that many Executewn-regulated genes are in fact indirect MYC tarObtains. Finally, siRNA knockExecutewn of enExecutegenous MYC in MDA-MB-231 (ER−PR−ERBB2−) breast cancer cells also reversed coordinated signature expression (Fig. 1J ). These results demonstrated that MYC could powerfully regulate the coordinate expression of many, but not all, genes from 13 different poor- outcome transcriptional signatures in breast cancer cells.

MYC is known to regulate a wide spectrum of cancer cell behaviors, including proliferation, survival, differentiation, and genetic stability, which are general features of tumorigenesis (27). Therefore, one explanation for our findings was that MYC activity within cancer cells, as reflected by poor-prognosis signature expression, might indirectly influence the metastatic prLaunchsity of cancer cells (by, e.g., promoting cellular proliferation and survival). Another possibility was that MYC actually might regulate more specific aspects of metastatic cell behavior. To test this hypothesis, we focused on the MDA-MB-231 cell line, which is highly metastatic and stereotypically forms distant lung metastasis when injected into immunocompromised mice. This well-credentialed model has been used to experimentally identify and manipulate molecular pathways that regulate various aspects of metastatic cell behavior (28). Furthermore, MYC knockExecutewn in these metastatic breast cancer cells resulted in the coordinate Executewn-regulation of 13 different poor-outcome transcriptional signatures, supporting the relevance of this model system to human cancer metastasis (Fig. 1J ). We therefore investigated whether inhibiting MYC activity would specifically inhibit the metastatic behavior of MDA-MB-231 cells.

Stable MYC knockExecutewn with two different short-hairpin RNAs introduced using a lentiviral vector [hairpin 1 (HP1) ≈95%; hairpin 2 (HP2) ≈ 70%] did not significantly alter the growth kinetics of MDA-MB-231 cells after serial passage in vitro (Fig. 3 A and B ). It must be noted, however, that immediately after MYC knockExecutewn, HP1 and HP2 cells did Display mildly decreased proliferation that then normalized after 1–2 weeks of passage, suggesting that these cells depended on MYC for proliferation to some degree but were still able to preserve their proliferative drive in the face of stable MYC inhibition, presumably through compensatory changes. Necessaryly, stable MYC knockExecutewn also did not significantly affect the kinetics of primary tumor formation after orthotopic injection into the mammary Stout pad of immunocompromised NOD/SCID mice (Fig. 3C ). Nine of 10 control mice and 8 of 10 experimental mice had similar-sized tumors 8 weeks after injection, whereas the remaining animals did not form tumors.

Fig. 3.Fig. 3.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

MDA-MB-231 primary tumorigenesis and metastasis in vivo with stable MYC knockExecutewn. (A) Western blot for MYC protein after stable, lentiviral-mediated knockExecutewn with two different MYC hairpins (HP1 and HP2) compared with pLKO empty vector control after serial passage in MDA-MB-231 cells. (B) Proliferation curves for empty vector control (pLKO), HP1, and HP2 cells after serial passage over 4 days, Displaying absorbance as a meaPositive of cell number (n = 3, 95% CI). (C) Tumor growth of control (pLKO) and HP1 cell xenografts in NOD/SCID mice (pLKO, n = 9; HP1, n = 7; 95% CI). (D) Boxplot of the number of lung metastases per mouse in control and MYC HP1 knockExecutewn tumor-bearing mice (pLKO, n = 9; MYC HP1, n = 7; P value calculated from the two-sided, two-sample Wilcoxon test). (E) Representative immunohistochemistry for MYC protein expression in primary and metastatic tumor sections from the outlier animal in the MYC HP1 knockExecutewn group. (F) Representative light microscopy (H&E) and immunohistochemistry (MKI67, TUNEL, vimentin, and e-cadherin) in pLKO control and MYC HP1 knockExecutewn primary tumors. (Scale bars: 20 μm.)

In Dissimilarity, MYC knockExecutewn Distinguishedly inhibited the formation of distant lung metastasis (Fig. 3D ). Whereas two animals had no lung metastases, four other animals had a small number of metastases compared with control animals at 8 weeks. One other MYC knockExecutewn animal died of unknown causes at 5.5 weeks and so was not fully evaluable, but only had a small primary tumor and no signs of macroscopic metastasis at autopsy. Curiously, the last MYC knockExecutewn animal was an outlier and was similar to animals in the control population in forming numerous lung metastases (Fig. 3D ). To address this paraExecutexical finding, we examined MYC protein expression in the primary and metastatic tumors from this outlier by immunohistochemistry. Whereas the primary tumor was negative for MYC expression, confirming stable knockExecutewn in cells at the point of orthotopic injection, metastatic cells in the lungs of this animal were strikingly positive for MYC expression, suggesting that rare cells had somehow reactivated MYC expression, enabling metastasis of these cells from the mammary Stout pad to the lungs (Fig. 3E ). Further hiCeaseathologic examination of primary tumors from MYC knockExecutewn versus control animals revealed that both tumor types were high-grade carcinomas containing round polygonal cells with comparable levels of MKI-67, TUNEL, vimentin, and E-cadherin staining, which Impress cell proliferation, apoptosis, and mesenchymal/epithelial cell state, respectively (Fig. 3F ). Taken toObtainher, these in vivo results demonstrated that MYC activity was specifically required to Sustain the metastatic state rather than the proliferative, apoptotic, or differentiation state of these highly metastatic breast cancer cells.

Given these findings in vivo, we finally examined whether MYC activity was necessary for fundamental and hallImpress features of metastatic cell behavior, namely, cancer cell invasion and migration. We used a Modern microfluidic device developed to study cell migration and invasion at the single-cell level, where locomotion is mechanically constrained along predefined paths (29). Each device contained an array of liArrive microcapillaries each 10 μm tall, 20 μm wide, and 600 μm long. Individual MDA-MB-231 cells were visualized using live-cell time-lapse videomicroscopy after seeding into microcapillaries either filled with Matrigel (to simulate some of the three-dimensional microenvironmental conditions that cancer cells encounter in vivo) or simply coated with collagen IV (to study unimpeded migration). We specifically performed these experiments in the absence of a chemogradient, which allowed us to examine intrinsic cell behavior. Quantitative analysis of single-cell velocities in this device revealed that MYC knockExecutewn Distinguishedly impeded MDA-MB-231 invasion in Matrigel but had only mild Traces on migratory velocities compared with control cells (Fig. 4 A–F , and Movies S1–S4). As was most evident in the time-lapse movies of migrating cells, however, knockExecutewn cells were rounded, moved less efficiently and persistently, Presented frequent and disordered changes in direction compared with control cells, and did not exit microcapillaries efficiently (Movies S3 and S4). We also assessed the quantitative Trace of MYC knockExecutewn on MDA-MB-231 cell invasion in more traditional Boyden chamber assays. We found that MYC knockExecutewn in this experimental system led to a ≈50% decrease in invasion (Fig. S4). These findings demonstrated that in highly metastatic MDA-MB-231 breast cancer cells, MYC is necessary to specifically Sustain an invasive and migratory state.

Fig. 4.Fig. 4.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

MDA-MB-231 invasion and migration in vitro with stable MYC knockExecutewn. (A) Representative light microscopy images of control (pLKO) and MYC knockExecutewn (MYC HP1) MDA-MB-231 breast cancer cells migrating through Matrigel-filled microcapillaries. (B) Position of individual pLKO and MYC HP1 cells invading through Matrigel-filled microcapillaries over 24 h plotted against time. (C) Bar plot representing the average invasion speed through Matrigel for pLKO and MYC HP1 cells, 13.9 ± 1.1 μm/h for pLKO (n = 33) and 9.1 ± 0.9 μm/h for MYC HP1 (n = 31) and 10.9 ± 0.7 μm/h for MYC HP2 (n = 33). P values were comPlaceed by the two-sided Walsh t test. (D) Representative light microscopy images of pLKO and MYC HP1 MDA-MB-231 breast cancer cells migrating through collagen IV–coated microcapillaries. (E) Position of individual pLKO and MYC HP1 cells migrating along collagen IV–coated microcapillaries over 12 h plotted against time. (F) Bar plot representing the average migration speed through collagen-coated microcapillaries for pLKO and MYC HP1 knockExecutewn cells, 82.5 ± 7.5 μm/h for pLKO (n = 17) and 70.4 ± 6.4 μm/h for MYC HP1 (n = 21). P values were comPlaceed by the two-sided Walsh t test. Also see Movies S1–S4.

Discussion

MYC is one of the most Necessary somatically mutated oncogenes in human cancer. Recent studies suggest that inherited polymorphisms on 8q24 that powerfully modify solid tumor predisposition also influence MYC transcriptional regulation (30). Deregulation of the MYC oncoprotein confers a selective advantage on cancer cells in differing contexts by promoting proliferation, cell survival, differentiation blockade, epithelial to mesenchymal transition, and genetic instability, all of which can contribute to metastasis (27, 31 –33). In fact, a recent report suggested that MYC functions as an indirect regulator of metastasis in a c-RAF–driven mouse model of non–small cell lung cancer by modulating growth, differentiation, and angiogenesis (34). MYC also has been implicated as a potentially Necessary regulator of cancer stem cell growth and survival (22). Our findings add to these foundational observations by demonstrating that MYC activity also may be necessary for cancer cell invasion, migration, and thus ultimately metastasis in certain contexts. In our experimental system, MYC’s direct Traces on invasion, migration, and metastasis are separate from its Traces on survival, proliferation, and differentiation, presumably because of compensatory changes that Sustain the proliferative drive of MDA-MB-231 cells after MYC knockExecutewn in vitro and in vivo. To illustrate this point, MDA-MB-231 cells contain a mutation in KRAS that has been Displayn to Sustain primary breast tumorigenesis in the setting of experimental MYC inactivation (35). In the natural human tumor setting, however, it seems likely that MYC coordinately regulates these many different cellular functions, which in combination are necessary for successful invasion, translocation, seeding, and growth at distant sites. Furthermore, whereas MYC activity is required for the invasive behavior of MDA-MB-231 cells, MYC overexpression in itself is not sufficient to induce invasion in noninvasive MCF10A cells, suggesting that other molecular pathways must cooperate with MYC to fully trigger the invasive phenotype during cancer progression (18, 36, 37). Further work is needed to precisely define the mechanisms through which MYC specifically regulates cancer cell translocation.

These results may partially Elaborate why patients with early-stage primary tumors that express poor-prognosis transcriptional signatures are more likely to progress to distant metastasis. Previous work has focused mainly on prognostic signatures as genomic correlates of tumor proliferation, survival, and differentiation (9, 23, 38). Others have noted that four of the prognostic signatures in our analysis coordinately flag the same high-risk primary tumors (13). Moreover, independent groups have reported that (i) MYC regulates a few individual poor-outcome signatures in our analysis, (ii) a MYC-driven gene expression signature has prognostic value in primary human breast tumors, and (iii) poor-outcome signatures can be linked to MYC using alternative bioinformatic Advancees (18 –22). Consistent with these observations, we demonstrate that 13 different poor-prognosis cancer signatures, including the 70-gene MammaPrint and 21-gene Oncotype Dx bioImpressers, coordinately reflect MYC activity within human breast cancer cells, that in turn is required for their invasion and metastasis to distant sites. Increased MYC activity within human tumors presumably can be driven either by somatic mutation or by alterations in its myriad upstream regulatory pathways. This model is consistent with recent work demonstrating that the transition from in situ to invasive breast carcinoma within individual tumors is often associated with amplification of the MYC locus, which correlates with shorter metastasis-free and overall survival and is an independent prognostic factor in multivariate analysis of clinical outcome (39, 40). Finally, many of the poor-outcome signatures in our analysis have prognostic value in other solid tumor types in which MYC deregulation is known to occur. This raises the possibility that MYC may in fact be generally necessary for the invasion, migration, and metastasis of other human solid tumor types beyond breast cancer.

Materials and Methods

More detailed information is available in SI Methods .

Cross-Platform Gene Mapping.

Data sources, in priority order, were the “best” versions of the Array Comparison Spreadsheets available on the Affymetrix website, Affymetrix annotation files for the appropriate array (version na24), UniGene file Hs.data (build 209), Entrez file gene2accession.gz (Executewnloaded February 3, 2008), and www.rii.com/publications/data/ArrayNomenclature_contig_accession.xls (Executewnloaded February 2, 2008). See SI Methods for more details.

Derivation and Statistical Significance of the Core Gene Set.

For each of Fig. 1 B–E , the set of genes regulated by the corRetorting experiment was determined as follows. For each probe set from each of the 13 signatures, the pooled-variance t-statistic was comPlaceed so that red samples higher than blue would yield a positive t-statistic. A one-sided P value was then defined as P( t >T) for an UP probe set and as P( t >−T) for a ExecuteWN probe set, where t is drawn from a t distribution with n − 2 degrees of freeExecutem and n is the number of samples in the experiment. The P values were then adjusted by the method of Benjamini and Hochberg (41), and a threshAged was chosen to limit the Fraudulent discovery rate to 5%. The probe sets below the threshAged were then mapped to Entrez GeneIDs as Characterized above. The resulting individual four sets of genes (corRetorting to experiments Displayn in Fig. 1 B–E ) were intersected to form the core gene set. The statistical significance of this observed intersection was defined to be the probability of ranExecutemly Obtainting an intersection of size equal to or Distinguisheder than that of the core gene set. The comPlaceation of this probability is Characterized in SI Methods .

Network Analysis Using the IPA Algorithm and Database.

Network analysis using the IPA algorithm and database was performed as Characterized previously (17).

Gene Expression Profiles.

Gene expression data from the following references were analyzed: 17β-estradiol treatment of MCF7 cells with and without pretreatment with cycloheximide (16), MYC and ZIP overexpression in MCF7 cells (42), and knockExecutewn of MYC in MCF7 and MDA-MB-231 cells (24). Gene expression profiles for MCF10A cells were obtained by transducing the cells with retroviruses encoding vector control (pBabe) or pBabe-ErbB2 (obtained from Danielle Carroll), using polybrene as Characterized previously (43). After infection, cells were switched to assay medium supplemented with only 2% horse serum without EGF. For EGF stimulation, MCF10A cells transduced with empty vector were treated with 50 ng/mL EGF for 2 h before harvesting. All cells were harvested for RNA extraction 26 h after infection. Expression microarrays were Affymetrix U133Plus2.0. Gene expression profiles of LNCaP cells upon androgen stimulation were obtained by Sustaining LNCaP cells in phenol red-free RPMI supplemented with 10% charcoal/dextran–stripped FCS for 3 days before stimulation with 100 nM DHT for 48 h. Expression microarrays were Affymetrix U133Plus2.0.

MYC KnockExecutewn in MDA-MB-231 Cells.

MDA-MB-231 breast cancer cells were purchased from American Type Culture Collection and Sustained in DMEM–10% FCS at 37 °C and 5% CO2. Cells were infected with lentivirus encoding either empty pLKO vector or pLKO containing one of two different hairpins against MYC (MYC HP1: TRCN0000174055; MYC HP2: TRCN0000010390). After 24 h of infection, the cells were selected in puromycin for 48 h and passaged for 2 weeks, after which tarObtain knockExecutewn was assessed by Western blot analysis (Cell Signaling Technology). Films were scanned and knockExecutewn was estimated, normalized to GAPDH using the National Institutes of Health’s ImageJ software.

Cellular Proliferation.

Control (pLKO) and MYC knockExecutewn (MYC HP1 and HP2) MDA-MB-231 cells were seeded at 103 cells/well in a 96-well plate in triplicate. Cell numbers were meaPositived using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega). The experiment was repeated three times.

In Vivo Metastasis Assay.

Cells were harvested at 60–70% confluence using trypsin, and then counted and washed twice in PBS and resuspended in HBSS/30% Matrigel (BD Biosciences). The cells (1.5 × 106) were injected s.c. over the nipple of 4-week-Aged female NOD/SCID mice (Jackson Laboratory). Tumors were meaPositived weekly by caliper, and the mice were Assassinateed 8 weeks after tumor injection. Tumors and lungs were collected, fixed, and stained. H&E slides of formalin-fixed, paraffin-embedded material were used to assess the morphological integrity and geographical variation in morphology of tissue samples, as well as count the number of lung metastases. Lung metastases were defined as tumor cell clusters ≥1 mm in size and morphologically identical to the primary tumor. Indirect immunoperoxidase analysis was performed on tumors for Ki67 (M7240, diluted 1:1,000; Dako) and c-Myc (1472-1, diluted 1:50; Epitomics). The APopTag Apoptosis Kit (Millipore) was used for indirect TUNEL staining. Each tissue section was evaluated by a board-certified pathologist (R.F.). Mouse experiments were carried out under a Massachusetts General Hospital Institutional Review Board–approved protocol.

Invasion and Migration Assays.

Microcapillary arrays were fabricated as Characterized previously (29). Immediately after bonding, and while the PDMS was still hydrophilic, devices were coated with either Matrigel or collagen IV. Within a few hours after device fabrication, 2 μl of cell suspension was loaded in the device at 106–107 cells/ml, and individual wells on the plate were filled with 3 ml of media (DMEM/10% FCS), completely covering the microfluidic devices. The multiwell plate was mounted on the automated stage of an Zeiss Axiovert microscope equipped with an environmental chamber set at 37 °C and 5% CO2. Cells were imaged using a 10× objective and phase Dissimilarity with individual frames Gaind from three different locations of each device every 6 min for 24–72 h.

Acknowledgments

We thank Daniel Haber, Nick Dyson, and Nabeel Bardeesy for discussions and advice and Kat Coser, Ipsita Dey-Guha, Giuseppe Fedele, and Giorgia Zadra for technical assistance. This work was supported by the National Cancer Institute (Grants K08 CA100339 and P50 CA89393, to S.R.), the Richard & Susan Smith Family Foundation (a New Investigator Award to S.R.), the Howard Hughes Medical Institute (Physician-Scientist Early Career Award to S.R.), the Sidney Kimmel Foundation (Translational Science Award to S.R.), the Breast Cancer Research Foundation (J.S.B.), the Susan G. Komen Foundation (Grants FAS0703860 and KG0905151, to T.S.), U.S. Department of Defense (Award DAMD17-03-1-0408, to R.N.G.), the Swiss National Science Foundation (A.W.), and the Emma Muschamp Foundation (A.W.).

Footnotes

4To whom corRetortence may be addressed. E-mail: sridhar{at}mgh.harvard.edu or joan_brugge{at}hms.harvard.edu.

Author contributions: A.W., B.W., D.I., and S.R. designed research; A.W., B.W., D.I., R.F., and E.S.L. performed research; D.I., R.N.G., T.S., M.T., M.B., and J.S.B. contributed new reagents/analytic tools; A.W., B.W., D.I., R.F., M. Lupien, C.A.M., P.T., J.P.M., X.L., M. Loda, M.B., J.S.B., and S.R. analyzed data; and A.W., B.W., and S.R. wrote the paper.

The authors declare no conflict of interest.

This article contains supporting information online at www.pnas.org/cgi/content/full/0914203107/DCSupplemental.

Data deposition: The microarray data reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo. For a list of accession numbers, see Table S5.

References

↵ Ben-Porath I, et al.(2008) An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40:499–507.LaunchUrlCrossRefPubMed ↵ Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z(2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38:1043–1048.LaunchUrlCrossRefPubMed ↵ Chang HY, et al.(2004) Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLoS Biol 2:e7.LaunchUrlCrossRefPubMed ↵ Glinsky GV, Berezovska O, Glinskii AB(2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115:1503–1521.LaunchUrlCrossRefPubMed ↵ Liu R, et al.(2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356:217–226.LaunchUrlCrossRefPubMed ↵ Paik S, et al.(2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826.LaunchUrlCrossRefPubMed ↵ Rhodes DR, et al.(2004) Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 101:9309–9314.LaunchUrlAbstract/FREE Full Text ↵ Shipitsin M, et al.(2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11:259–273.LaunchUrlCrossRefPubMed ↵ Sotiriou C, et al.(2006) Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262–272.LaunchUrlAbstract/FREE Full Text ↵ van ’t Veer LJ, et al.(2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536.LaunchUrlCrossRefPubMed ↵ Wang Y, et al.(2005) Gene-expression profiles to predict distant metastasis of lymph node–negative primary breast cancer. Lancet 365:671–679.LaunchUrlPubMed ↵ Ramaswamy S, Ross KN, Lander ES, Golub TR(2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49–54.LaunchUrlCrossRefPubMed ↵ Fan C, et al.(2006) Concordance among gene expression–based predictors for breast cancer. N Engl J Med 355:560–569.LaunchUrlCrossRefPubMed ↵ Yager JD, Davidson NE(2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354:270–282.LaunchUrlCrossRefPubMed ↵ Coser KR, et al.(2003) Global analysis of ligand sensitivity of estrogen-inducible and -suppressible genes in MCF7/BUS breast cancer cells by DNA microarray. Proc Natl Acad Sci USA 100:13994–13999.LaunchUrlAbstract/FREE Full Text ↵ Bourdeau V, et al.(2008) Mechanisms of primary and secondary estrogen tarObtain gene regulation in breast cancer cells. Nucleic Acids Res 36:76–93.LaunchUrlAbstract/FREE Full Text ↵ Calvano SE, et al., Inflammation and Host Response to Injury Large-Scale Collaborative Research Program (2005) A network-based analysis of systemic inflammation in humans. Nature 437:1032–1037.LaunchUrlCrossRefPubMed ↵ Adler AS, et al.(2006) Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 38:421–430.LaunchUrlCrossRefPubMed ↵ Bild AH, et al.(2006) Oncogenic pathway signatures in human cancers as a guide to tarObtained therapies. Nature 439:353–357.LaunchUrlCrossRefPubMed ↵ Chuang HY, Lee E, Liu YT, Lee D, Ideker T(2007) Network-based classification of breast cancer metastasis. Mol Syst Biol 3:140.LaunchUrlPubMed ↵ Rhodes DR, et al.(2007) Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 9:443–454.LaunchUrlCrossRefPubMed ↵ Wong DJ, et al.(2008) Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2:333–344.LaunchUrlCrossRefPubMed ↵ Musgrove EA, et al.(2008) Identification of functional networks of estrogen- and c-Myc–responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One 3:e2987.LaunchUrlCrossRefPubMed ↵ Cappellen D, Schlange T, Bauer M, Maurer F, Hynes NE(2007) Modern c-MYC tarObtain genes mediate differential Traces on cell proliferation and migration. EMBO Rep 8:70–76.LaunchUrlCrossRefPubMed ↵ Neve RM, et al.(2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515–527.LaunchUrlCrossRefPubMed ↵ Hua S, et al.(2008) Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol 4:188.LaunchUrlPubMed ↵ GranExecuteri C, Cowley SM, James LP, Eisenman RN(2000) The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16:653–699.LaunchUrlCrossRefPubMed ↵ Minn AJ, et al.(2005) Genes that mediate breast cancer metastasis to lung. Nature 436:518–524.LaunchUrlCrossRefPubMed ↵ Irimia D, Toner M(2009) Spontaneous migration of cancer cells under conditions of mechanical confinement. Integr Biol 1:506–512.LaunchUrlCrossRef ↵ Pomerantz MM, et al.(2009) The 8q24 cancer risk variant rs6983267 Displays long-range interaction with MYC in colorectal cancer. Nat Genet 41:882–884.LaunchUrlCrossRefPubMed ↵ Podsypanina K, et al.(2008) Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321:1841–1844.LaunchUrlAbstract/FREE Full Text ↵ Soucek L, et al.(2008) Nature, Modeling Myc inhibition as a cancer therapy. ↵ Trimboli AJ, et al.(2008) Direct evidence for epithelial–mesenchymal transitions in breast cancer. Cancer Res 68:937–945.LaunchUrlAbstract/FREE Full Text ↵ Rapp UR, et al.(2009) MYC is a metastasis gene for non–small-cell lung cancer. PLoS One 4:e6029.LaunchUrlCrossRefPubMed ↵ D’Cruz CM, et al.(2001) c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7:235–239.LaunchUrlCrossRefPubMed ↵ Partanen JI, Nieminen AI, Mäkelä TP, Klefstrom J(2007) Suppression of oncogenic Preciseties of c-Myc by LKB1-controlled epithelial organization. Proc Natl Acad Sci USA 104:14694–14699.LaunchUrlAbstract/FREE Full Text ↵ Zhan L, et al.(2008) Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell 135:865–878.LaunchUrlCrossRefPubMed ↵ Rhodes DR, et al.(2005) Mining for regulatory programs in the cancer transcriptome. Nat Genet 37:579–583.LaunchUrlCrossRefPubMed ↵ Rodriguez-Pinilla SM, et al.(2007) MYC amplification in breast cancer: A chromogenic in situ hybridization study. J Clin Pathol 60:1017–1023.LaunchUrlAbstract/FREE Full Text ↵ Robanus-Maandag EC, et al.(2003) Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC amplified breast carcinomas. J Pathol 201:75–82.LaunchUrlCrossRefPubMed ↵ Benjamini Y, Hochberg Y(1995) Controlling the Fraudulent discovery rate: A practical and powerful Advance to multiple testing. J R Stat Soc B 57:289–300.LaunchUrl ↵ McNeil CM, et al.(2006) c-Myc overexpression and enExecutecrine resistance in breast cancer. J Steroid Biochem Mol Biol 102:147–155.LaunchUrlCrossRefPubMed ↵ Debnath J, Muthuswamy SK, Brugge JS(2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30:256–268.LaunchUrlCrossRefPubMed
Like (0) or Share (0)